Biologic basis for interleukin-1 in disease
WebTo understand the role of the proinflammatory cytokine interleukin-1 (IL-1) in disease, investigators have studied how production of the different members of the IL-1 family is … WebFeb 23, 2010 · Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary …
Biologic basis for interleukin-1 in disease
Did you know?
WebEosinophils play a key role in airway inflammation in many diseases, such as allergic and non-allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. In these chronic disabling conditions, eosinophils contribute to tissue damage, repair, remodeling, and disease persistence through the production a variety of … WebJun 6, 2024 · Interleukin-1, an inflammatory cytokine, is considered to have diverse physiological functions and pathological significances and play an important role in health and disease. In this decade, interleukin-1 family members have been expanding and evidence is accumulating that highlights the importance of interleukin-1 in linking innate …
WebTo understand the role of the proinflammatory cytokine interleukin-1 (IL-1) in disease, investigators have studied how production of the different members of the IL-1 family is controlled, the various biologic activities of IL-1, the distinct and various functions of the IL-1 receptor (IL-1R) family, and the complexity of intracellular signaling. WebApr 4, 2011 · Introduction. Since the 1996 publication in Blood of “Biologic Basis for Interleukin-1 in Disease,” 1 there have been several major advances in understanding …
WebOct 31, 2024 · One inflammatory mediator has come to the fore as a therapeutic target in cardiovascular disease. The experimental and clinical evidence reviewed here support interleukin-1 beta (IL-1β) as both a local vascular and systemic contributor in this regard. Intrinsic vascular wall cells and lesional leukocytes alike can produce this cytokine. WebObjective Although interleukin (IL)-1/IL-6 inhibitors are effective therapies ... Incidence and risk factors for eosinophilia and lung disease in biologic-exposed children with systemic juvenile idiopathic arthritis ... Human leukocyte antigen (HLA) typing was performed on a clinical or research basis. Results. There were 264 new medication ...
WebThe basis for the term "interleukin" was to streamline the growing number of biological properties attributed to soluble factors from macrophages and lymphocytes. IL-1 was the …
WebAug 27, 2024 · What they target: interleukin-1, interleukin-6, interleukin-12, ... How often you need treatment and the way you receive it depends on your type of autoimmune disease, and which biologic you take ... rob heydonWebMar 1, 1996 · To understand the role of the proinflammatory cytokine interleukin-1 (IL-1) in disease, investigators have studied how production of the different members of the IL-1 … rob heylandWebThe proinflammatory cytokine interleukin (IL)-1β is emerging as a key mediator of many pathophysiological events that characterise host-environment interactions. In this article we discuss the role of IL-1β in H pylori associated disease. The key pathophysiological event in H pylori infection is initiation of an inflammatory response. rob heyman vubWebObjective: Although interleukin (IL)-1/IL-6 inhibitors are effective therapies for systemic juvenile idiopathic arthritis (sJIA), some patients develop eosinophilia and lung disease (LD) during treatment. We retrospectively evaluated incidence and risk factors for eosinophilia and described LD outcomes in IL-1/IL-6 inhibitor-exposed patients with sJIA. rob heydon productions inc. logoWebFeb 23, 2010 · Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood 87, 2095–2147 (1996). CAS PubMed Google Scholar Chung, Y. et al. Critical regulation of early Th17 cell differentiation by ... rob heyland actorWebfactor (TNF) or interleukin (IL) molecules, among other mechanisms. These agents carry specific safety warnings. Table 1-2 provides a summary of the available biologic DMARDs and tofacitinib. The ACR criteria have become widely used in clini-cal trials as a marker for efficacy for the treatment of RA. Abbreviations in This Chapter rob hezel racing foundationWebMar 15, 1996 · Biologic basis for interleukin-1 in disease. Blood (1996) 87 (6): 2095–2147. To understand the role of the proinflammatory cytokine interleukin-1 (IL-1) … rob heymanns gmbh